Critical analysis of rituximab-induced serological changes in connective tissue diseases

Autoimmunity Reviews

Volumn 8, Issue 6, 2009, Pages 515-519

  Cornec, D ^a,b,c   Avouac, J ^d   Youinou, P ^a,c   Saraux, A ^a,b  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c CHU MORVAN   (France)

^d Hôpital Cochin ^*  (France)

Author keywords

Autoantibody; B lymphocyte; BAFF; Connective tissue diseases; Immunoglobulin; Rituximab

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; CD20 ANTIBODY; COMPLEMENT COMPONENT C1Q ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DNA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LA ANTIBODY; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB; RO ANTIBODY; SM ANTIBODY;

ANTIBODY TITER; AUTOIMMUNE DISEASE; CONNECTIVE TISSUE DISEASE; DRUG MECHANISM; EMBASE; HUMAN; MEDLINE; PLASMA CELL; REVIEW; RHEUMATOID ARTHRITIS; SEROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, NUCLEAR; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; COMPLEMENT C1Q; CONNECTIVE TISSUE DISEASES; DATABASES, BIBLIOGRAPHIC; HUMANS; LYMPHOCYTE DEPLETION; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; TREATMENT OUTCOME;

EID: 67349186964     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.01.007     Document Type: Review

References (40)

1. Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., and Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189 (1999) 1639-1648
2. Edwards J.C., Cambridge G., and Abrahams V.M. Do self-perpetuating B lymphocytes drive human autoimmune disease?. Immunology 97 (1999) 188-196
3. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2 (2001) 764-766
4. Youinou P., Daridon C., Saraux A., Devauchelle V., and Pers J. Is B-cell the conductor of the lymphocyte orchestra in the salivary glands of patients with primary Sjögren's syndrome. Clin Exp Rheumatol 24 (2006) 491-492
5. Edwards J.C., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40 (2001) 205-211
6. Binard A., Le Pottier L., Saraux A., Devauchelle-Pensec V., Pers J., and Youinou P. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?. J Autoimmun 30 (2008) 63-67
7. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006) 2793-2806
8. Keystone E., Fleischmann R., Emery P., Furst D.E., van Vollenhoven R., Bathon J., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56 (2007) 3896-3908
9. Cambridge G., Leandro M.J., Teodorescu M., Manson J., Rahman A., Isenberg D.A., et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54 (2006) 3612-3622
10. Cambridge G., Stohl W., Leandro M.J., Migone T., Hilbert D.M., and Edwards J.C.W. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54 (2006) 723-732
11. Cambridge G., Leandro M.J., Edwards J.C.W., Ehrenstein M.R., Salden M., Bodman-Smith M., et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48 (2003) 2146-2154
12. Bokarewa M., Lindholm C., Zendjanchi K., Nadali M., and Tarkowski A. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol 66 (2007) 476-483
13. Toubi E., Kessel A., Slobodin G., Boulman N., Pavlotzky E., Zisman D., et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 818-820
14. Teng Y.K.O., Levarht E.W.N., Hashemi M., Bajema I.M., Toes R.E.M., Huizinga T.W.J., et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 56 (2007) 3909-3918
15. Rosengren S., Wei N., Kalunian K.C., Zvaifler N.J., Kavanaugh A., and Boyle D.L. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther 10 (2008) R105
16. Thurlings R.M., Vos K., Wijbrandts C.A., Zwinderman A.H., Gerlag D.M., and Tak P.P. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 67 (2008) 917-925
17. Jónsdóttir T., Gunnarsson I., Risselada A., Henriksson E.W., Klareskog L., and van Vollenhoven R.F. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 67 (2008) 330-334
18. Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., and Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44 (2005) 1542-1545
19. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 (2004) 2580-2589
20. Vigna-Perez M., Hernández-Castro B., Paredes-Saharopulos O., Portales-Pérez D., Baranda L., Abud-Mendoza C., et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8 (2006) R83
21. Anolik J.H., Barnard J., Cappione A., Pugh-Bernard A.E., Felgar R.E., Looney R.J., et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50 (2004) 3580-3590
22. Lindholm C., Börjesson-Asp K., Zendjanchi K., Sundqvist A., Tarkowski A., and Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 35 (2008) 826-833
23. Deshmukh U.S., Bagavant H., and Fu S.M. Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun Rev 5 (2006) 414-418
24. Miltenburg A.M., Roos A., Slegtenhorst L., Daha M.R., and Breedveld F.C. IgA anti-dsDNA antibodies in systemic lupus erythematosus: occurrence, incidence and association with clinical and laboratory variables of disease activity. J Rheumatol 20 (1993) 53-58
25. Vallerskog T., Gunnarsson I., Widhe M., Risselada A., Klareskog L., van Vollenhoven R., et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 122 (2007) 62-74
26. Vos K., Thurlings R.M., Wijbrandts C.A., van Schaardenburg D., Gerlag D.M., and Tak P.P. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 56 (2007) 772-778
27. Kavanaugh A., Rosengren S., Lee S.J., Hammaker D., Firestein G.S., Kalunian K., et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 67 (2008) 402-408
28. Atzeni F., Doria A., Maurizio T., and Sarzi-Puttini P. What is the role of rituximab in the treatment of rheumatoid arthritis?. Autoimmun Rev 6 (2007) 553-558
29. Vallerskog T., Heimbürger M., Gunnarsson I., Zhou W., Wahren-Herlenius M., Trollmo C., et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 8 (2006) R167
30. Pers J., Devauchelle V., Daridon C., Bendaoud B., Le Berre R., Bordron A., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 56 (2007) 1464-1477
31. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190 (1999) 1697-1710
32. Pers J., Daridon C., Devauchelle V., Jousse S., Saraux A., Jamin C., et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050 (2005) 34-39
33. Anolik J.H., Barnard J., Owen T., Zheng B., Kemshetti S., Looney R.J., et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56 (2007) 3044-3056
34. Ng K.P., Cambridge G., Leandro M.J., Edwards J.C.W., Ehrenstein M., and Isenberg D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 66 (2007) 1259-1262
35. Pijpe J., van Imhoff G.W., Spijkervet F.K.L., Roodenburg J.L.N., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 52 (2005) 2740-2750
36. William J., Euler C., and Shlomchik M.J. Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. J Immunol 174 (2005) 6879-6887
37. Devauchelle-Pensec V., Pennec Y., Morvan J., Pers J., Daridon C., Jousse-Joulin S., et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 57 (2007) 310-317
38. De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., and Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46 (2002) 2029-2033
39. Kneitz C., Wilhelm M., and Tony H.P. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol 33 (2004) 82-86
40. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400